{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:42:13Z","timestamp":1775857333307,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11739-020-02622-7","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T09:03:02Z","timestamp":1611738182000},"page":"1559-1565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48\u00a0weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-0479","authenticated-orcid":false,"given":"Shima","family":"Mimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Oura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tadokoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Himoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"2622_CR1","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HLY, Lok A (2014) Hepatitis B virus infection. Lancet 384:2053\u20132063","journal-title":"Lancet"},{"key":"2622_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97\u2013107","journal-title":"J Viral Hepat"},{"key":"2622_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1440-1746.1997.tb00513.x","volume":"12","author":"CJ Chen","year":"1997","unstructured":"Chen CJ, Yu MW, Liaw YF (1997) Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastoenterol Hepatol 12:294\u2013298","journal-title":"J Gastoenterol Hepatol"},{"key":"2622_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65\u201373","journal-title":"JAMA"},{"key":"2622_CR5","first-page":"401","volume":"58","author":"M Martinot-Peignoux","year":"2013","unstructured":"Martinot-Peignoux M, Lapalus M, Laou\u00e9nan C et al (2013) Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J ClinVirol 58:401\u2013407","journal-title":"J ClinVirol"},{"key":"2622_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/hepr.12444","volume":"45","author":"LS Qu","year":"2015","unstructured":"Qu LS, Liu JX, Zhang HF, Zhu J, Lu CH (2015) Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: a meta-analysis. Hepatol Res 45:1004\u20131013","journal-title":"Hepatol Res"},{"key":"2622_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"57","author":"A Ono","year":"2012","unstructured":"Ono A, Suzuki F, Kawamura Y (2012) Long-term continuous entecavir therapy in nucleos(t)ide-na\u00efve chronic hepatitis B patients. J Hepatol 57:508\u2013514","journal-title":"J Hepatol"},{"key":"2622_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","volume":"142","author":"TC Tseng","year":"2012","unstructured":"Tseng TC, Liu CJ, Yang HC et al (2012) High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142:1140\u20131149","journal-title":"Gastroenterology"},{"key":"2622_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1245\/s10434-014-4043-5","volume":"22","author":"WR Liu","year":"2015","unstructured":"Liu WR, Tian MX, Jin L et al (2015) High levels of hepatitis b surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads. Ann Surg Oncol 22:843\u2013850","journal-title":"Ann Surg Oncol"},{"key":"2622_CR10","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jvh.12211","volume":"21","author":"T Hara","year":"2014","unstructured":"Hara T, Suzuki F, Kawamura Y et al (2014) Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-na\u00efve chronic hepatitis B patients. J Viral Hepat 21:802\u2013808","journal-title":"J Viral Hepat"},{"key":"2622_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/hep.22760","volume":"49","author":"MR Brunetto","year":"2009","unstructured":"Brunetto MR, Moriconi F, Bonino F (2009) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49:1141\u20131150","journal-title":"Hepatology"},{"key":"2622_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","volume":"138","author":"JD Chen","year":"2010","unstructured":"Chen JD, Yang HI, Iloeje UH et al (2010) Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138:1747\u20131754","journal-title":"Gastroenterology"},{"key":"2622_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","volume":"50","author":"R Moucari","year":"2009","unstructured":"Moucari R, Korevaar A, Lada O et al (2009) High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 50:1084\u20131092","journal-title":"J Hepatol"},{"key":"2622_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23722","volume":"52","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst V, Hansen B, Cakaloglu Y et al (2010) Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52:454\u2013461","journal-title":"Hepatology"},{"key":"2622_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.26041","volume":"57","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Yang HC et al (2013) Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 57:441\u2013450","journal-title":"Hepatology"},{"key":"2622_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/infdis\/jit209","volume":"208","author":"TC Tseng","year":"2013","unstructured":"Tseng TC, Liu CJ, Chen CL et al (2013) Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 208:584\u2013593","journal-title":"J Infect Dis"},{"key":"2622_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK et al (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10:1\u201398","journal-title":"Hepatol Int"},{"key":"2622_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00535-013-0821-2","volume":"49","author":"M Kobayashi","year":"2014","unstructured":"Kobayashi M, Hosaka T, Suzuki F, Akuta N et al (2014) Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol 49:538\u2013546","journal-title":"J Gastroenterol"},{"key":"2622_CR19","first-page":"559","volume":"130","author":"MH Li","year":"2017","unstructured":"Li MH, Zhang L, Qu XJ et al (2017) Kinetics of hepatitis B surface antigen level in chronic hepatitis B patients who achieved hepatitis B surface antigen loss during pegylated interferon alpha-2a treatment. Med J (Engl) 130:559\u2013565","journal-title":"Med J (Engl)"},{"key":"2622_CR20","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.22744","volume":"49","author":"R Moucari","year":"2009","unstructured":"Moucari R, Mackiewicz V, Lada O et al (2009) Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151\u20131157","journal-title":"Hepatology"},{"key":"2622_CR21","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa0912696","volume":"364","author":"H Wedemeyer","year":"2011","unstructured":"Wedemeyer H, Yurdaydin C, Dalekos GN et al (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364:322\u2013331","journal-title":"N Engl J Med"},{"key":"2622_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jhep.2014.08.021","volume":"62","author":"P Marcellin","year":"2015","unstructured":"Marcellin P, Avila C, Wursthorn K et al (2015) Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 62:41\u201347","journal-title":"J Hepatol"},{"key":"2622_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jvh.12018","volume":"20","author":"L Boglione","year":"2013","unstructured":"Boglione L, D\u2019Avolio A, Cariti G et al (2013) Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 20:11\u201319","journal-title":"J Viral Hepat"},{"key":"2622_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3851\/IMP1866","volume":"16","author":"J Jaroszewicz","year":"2011","unstructured":"Jaroszewicz J, Ho H, Markova A et al (2011) B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues. Antivir Ther 16:915\u2013924","journal-title":"Antivir Ther"},{"key":"2622_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcv.2012.01.024","volume":"54","author":"JM Kittner","year":"2012","unstructured":"Kittner JM, Sprinzl MF, Grambihler A et al (2012) Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 54:93\u201395","journal-title":"J Clin Virol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-020-02622-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-020-02622-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T04:15:00Z","timestamp":1628568900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-020-02622-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2622"],"URL":"https:\/\/doi.org\/10.1007\/s11739-020-02622-7","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,27]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for this study was obtained from ethical committee of Kagawa University, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}